Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
Intérêt de la radiothérapie Adaptative en stéréotaxie Prostatique
Clinique Sainte Clotilde
100 participants
Nov 18, 2025
INTERVENTIONAL
Conditions
Summary
This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer. Five low-dose CT scans are performed before each SBRT session to assess anatomical variations (bladder filling, rectal volume) and determine if a dosimetric recalculation would have been required. The study also evaluates cumulative dose to organs at risk, patient-reported quality of life over 24 months, and overall and recurrence-free survival.
Eligibility
Inclusion Criteria9
- Male aged ≥60 years
- Localized prostate cancer of low or intermediate risk (T1-T2)
- Gleason score 6-7
- PSA \<15 ng/mL
- No evidence of metastatic disease
- Radiotherapy indicated for prostate cancer
- Affiliated with or benefiting from a French social security system
- French-speaking patient
- Patient appropriately informed and having signed a written informed consent form
Exclusion Criteria7
- Unable to read, write, or understand French
- Vulnerable patient as defined by Article L1121-6 of the French Public Health Code
- Adult under guardianship, curatorship, or legal protection ("sauvegarde de justice")
- Patient unable to personally provide informed consent according to Article L1121-8 of the French Public Health Code
- Patient already included in another interventional study that could interfere with study outcomes
- History of urological (prostate) or digestive surgery that could influence study outcomes
- Refusal to sign the written informed consent form
Interventions
Five low-dose, non-contrast CT scans performed immediately before each SBRT session (≈10 min before treatment) to assess anatomical variations impacting target volume and organ-at-risk dosimetry.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07344844